Medical Devices - Hearing Implants & Audiology Solutions
Strategic Profile
The Acclaim Cochlear Implant is designed to be the first fully implanted cochlear implant, featuring a sensor designed to leverage the natural anatomy of the ear instead of a microphone to capture sound. The device received FDA Breakthrough Device Designation in 2019. As of April 2026, the company completed enrollment of its pivotal clinical trial with all 56 patients having completed their activation visits.
Cyborg Score Rationale
The company recently regained NASDAQ listing compliance after securing $30 million in an upsized public offering in February 2026. Envoy achieved full enrollment of its U.S. pivotal trial, positioning it as the first cochlear implant company to do so. However, as an early-stage medical device company with investigational technology and minimal historical revenue, execution risk remains significant.
Top Insights
Clinical inflection point: Pivotal trial enrollment complete as of April 2026 with all 56 patients through activation visits, setting stage for regulatory submission
Capital raised: $30M upfront in February 2026 upsized offering with potential $48M additional tranches to fund commercialization
IP strengthening: Three new patents issued in February 2026 (one US, two Hong Kong) reinforcing competitive moat in fully-implanted cochlear implant space
Board augmentation: Appointed seasoned med-tech executive Chas McKhann to Board in April 2026 to bolster commercialization expertise
Named Competitors
Cochlear CI — Market-leading external cochlear implants with miniaturization initiatives